Nasdaq:US$10.71 (+0.26) | HKEX:HK$16.88 (-0.24) | AIM:£1.80 (+0.02)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors